Biotech company Valo Health and AI healthcare firm nference have entered into a multi-year partnership to leverage AI and patient data in drug discovery and development.
The collaboration will integrate nference’s AI platform, which processes de-identified data from top academic medical centers, with Valo’s Opal Computational platform to enhance target discovery and precision medicine, according to a news release shared with Becker’s.
The partnership also grants Valo access to insights from physician notes, medical imaging, lab results and treatment data, which could help accelerate drug development.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
